enzastaurin

08/01/2011 - "Enzastaurin can inhibit tumor growth and improve the efficacy of radiation for HNSCC both in vitro and in vivo. "
10/01/2010 - "Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors."
04/01/2009 - "Among a myriad of molecules able to modulate PKC activity, we will focus on the role of the enzastaurin and briostatin-1, which already entered clinical trials for several human cancers."
11/15/2007 - "Targeting PKCbeta with enzastaurin, a well-tolerated drug in clinical trials, would be expected to radiosensitize pancreatic tumors through direct antitumor and antivascular effects. "
08/01/2007 - "In the present review, we summarize the rationale for targeting PKC in cancer, the preclinical experience of enzastaurin, and the clinical findings of the current phase I and II studies. "

03/01/2010 - "We examined the efficacy of enzastaurin plus pemetrexed as second-line therapy in patients with advanced (stage IIIA/B or IV) non-small cell lung cancer in a double-blinded, randomized, phase II study. "
10/01/2012 - "A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer."
07/01/2010 - "A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer."
03/01/2010 - "Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer."
07/01/2010 - "Both schedules of enzastaurin in combination with pemetrexed were well tolerated and clinically active in patients with advanced non-small cell lung cancer."

08/01/2013 - "A multicenter, open-label, noncomparative screening study of enzastaurin in adult patients with non-Hodgkin lymphomas."
08/01/2011 - "Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies."
06/01/2006 - "Phase II trials of enzastaurin in recurrent high-grade gliomas and lymphomas have shown promising results. "
10/01/2012 - "The purpose of the present study was to assess the antitumour activity of the combination of low doses of Enzastaurin and Lenalidomide (Revlimid) on B-lymphoma cell lines. "
10/01/2012 - "The combination of Enzastaurin and Lenalidomide, at doses as low as 1 μM, showed strong synergism against indolent lymphomas by reducing cell growth, producing an increase in G0-G1 phase followed by significant decrease in S phase, increasing apoptosis, and inhibiting PI3K/AKT, PKC and MAPK/ERK pathways. "

09/08/2008 - "The initial objective of this study was to assess the efficacy of enzastaurin in a series of malignant human glioma cell lines with diverse genomic alterations. "
02/01/2010 - "A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas."
05/15/2009 - "Enzastaurin has activity in a subset of malignant glioma patients and warrants continued study in combination with other agents using a maximal once daily dose of 500 mg."
05/15/2009 - "A phase I trial of enzastaurin in patients with recurrent gliomas."
02/01/2010 - "Enzastaurin has anti-glioma activity in patients with recurrent high-grade glioma, but does not appear to have enough single-agent activity to be useful as monotherapy."

05/01/2014 - "Novel therapies, including enzastaurin, in the treatment of ovarian cancer."
08/18/2009 - "Therefore, the combinational effect of enzastaurin and pemetrexed can have promise in clinical application to overcome the fast-growing development of resistance to chemotherapy in ovarian cancer."
09/01/2013 - "Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer."
07/01/2010 - "In this study the modulatory effect of the proteinase kinase C beta (PKC beta) selective inhibitor enzastaurin on CA125 expression and shedding in ovarian cancer cells (OVCAR-3 cells) was investigated. "
07/01/2010 - "The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells."